JP2018520669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520669A5 JP2018520669A5 JP2017565788A JP2017565788A JP2018520669A5 JP 2018520669 A5 JP2018520669 A5 JP 2018520669A5 JP 2017565788 A JP2017565788 A JP 2017565788A JP 2017565788 A JP2017565788 A JP 2017565788A JP 2018520669 A5 JP2018520669 A5 JP 2018520669A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- mirna
- engineered
- output
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700011259 MicroRNAs Proteins 0.000 claims 14
- 239000002679 microRNA Substances 0.000 claims 14
- 230000002068 genetic effect Effects 0.000 claims 10
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 239000002458 cell surface marker Substances 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101710195517 Histone H2AX Proteins 0.000 claims 1
- 101000880769 Homo sapiens Protein SSX1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100037687 Protein SSX1 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000000717 tumor promoter Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181906P | 2015-06-19 | 2015-06-19 | |
| US62/181,906 | 2015-06-19 | ||
| US201662325314P | 2016-04-20 | 2016-04-20 | |
| US62/325,314 | 2016-04-20 | ||
| PCT/US2016/038222 WO2016205737A2 (en) | 2015-06-19 | 2016-06-17 | Tumor immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520669A JP2018520669A (ja) | 2018-08-02 |
| JP2018520669A5 true JP2018520669A5 (https=) | 2019-07-18 |
Family
ID=57546436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565788A Pending JP2018520669A (ja) | 2015-06-19 | 2016-06-17 | 腫瘍免疫療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190002912A1 (https=) |
| EP (1) | EP3310915A4 (https=) |
| JP (1) | JP2018520669A (https=) |
| CN (1) | CN108350445A (https=) |
| AU (1) | AU2016279050A1 (https=) |
| HK (1) | HK1257177A1 (https=) |
| WO (1) | WO2016205737A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102763121B1 (ko) | 2015-02-06 | 2025-02-04 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| WO2018022747A1 (en) | 2016-07-26 | 2018-02-01 | Senti Biosciences, Inc. | Genetic erasers |
| WO2018169901A1 (en) * | 2017-03-13 | 2018-09-20 | Massachusetts Institute Of Technology | Synthetic promoters |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN112654711B (zh) * | 2018-08-29 | 2024-03-26 | 上海科技大学 | Cas蛋白抑制剂的组合物及应用 |
| US12398428B2 (en) * | 2019-02-06 | 2025-08-26 | Cornell University | DARC expression as prognosticator of immunotherapy outcomes |
| JP2023504884A (ja) * | 2019-12-05 | 2023-02-07 | ヴィセリックス・インコーポレーティッド | ユニバーサル細胞療法のための免疫逃避機構のモジュレーター |
| CN116859048A (zh) * | 2022-12-09 | 2023-10-10 | 上海交通大学医学院附属第九人民医院 | 肿瘤标志物跨膜蛋白slc31a1及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| WO2008134593A1 (en) * | 2007-04-25 | 2008-11-06 | President And Fellows Of Harvard College | Molecular circuits |
| EP3444346B1 (en) * | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2016
- 2016-06-17 CN CN201680035950.5A patent/CN108350445A/zh active Pending
- 2016-06-17 WO PCT/US2016/038222 patent/WO2016205737A2/en not_active Ceased
- 2016-06-17 US US15/737,829 patent/US20190002912A1/en not_active Abandoned
- 2016-06-17 JP JP2017565788A patent/JP2018520669A/ja active Pending
- 2016-06-17 HK HK18116072.7A patent/HK1257177A1/zh unknown
- 2016-06-17 AU AU2016279050A patent/AU2016279050A1/en not_active Abandoned
- 2016-06-17 EP EP16812575.5A patent/EP3310915A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520669A5 (https=) | ||
| D’Alise et al. | Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade | |
| Basile et al. | Immunotherapy for colorectal cancer: where are we heading? | |
| Woller et al. | Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses | |
| JP2017509350A5 (https=) | ||
| KR20180054600A (ko) | 면역치료에서의 대식세포 키메라 항원 수용체(moto-car) | |
| JP2019527563A5 (https=) | ||
| JP2008545406A5 (https=) | ||
| JP2021518161A5 (https=) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| JP2021518162A5 (https=) | ||
| JP2017524341A5 (https=) | ||
| US20170166657A1 (en) | Macrophage CAR (MOTO-CAR) In Immunotherapy | |
| JP2018522072A5 (https=) | ||
| Vienot et al. | Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy | |
| JP2018526323A5 (https=) | ||
| Kottke et al. | Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy | |
| HRP20220525T1 (hr) | Postupci uporabe polinukleotida koji kodiraju ligand ox40 | |
| WO2019199994A1 (en) | Therapeutic constructs for treating cancer | |
| CN101899434A (zh) | 一种可连接多片段的重叠延伸pcr方法 | |
| JP2022544337A (ja) | 細胞の標的化および標識化に使用する抗ｃｄ３アプタマー | |
| JP2014505014A5 (https=) | ||
| Shimoda et al. | Virally encoded interleukin-6 facilitates KSHV replication in monocytes and induction of dysfunctional macrophages | |
| Aoki et al. | Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses | |
| EP4685161A3 (en) | Oncolytic virotherapy and immunotherapy |